Target intelligence / Profile preview

Coagulation factor Xa and thrombin (serine proteases of coagulation) (Factor Xa (FXa), Thrombin (FIIa))

Target
Factor Xa (FXa), Thrombin (FIIa)
Molecular classification
Enzyme, Serine protease (trypsin-like), Protease (EC class 3.4.21), Blood coagulation factor, Endopeptidase (for Thrombin specifically), Endopeptidase (for Factor Xa specifically)
01

Overview

Coagulation factor Xa and thrombin are central serine protease enzymes in the blood coagulation cascade. Factor Xa cleaves prothrombin to generate thrombin (activated Factor II), which then converts fibrinogen to fibrin, resulting in clot formation. These proteases possess a characteristic serine protease catalytic triad and are regulated by endogenous inhibitors (serpins) and several anticoagulant drug classes. They are tightly controlled to prevent both thrombosis and excessive bleeding. Beyond coagulation, these enzymes contribute to inflammatory signaling, vascular biology, and tissue repair. Pharmacological inhibition of factor Xa and thrombin is a mainstay for the prevention and treatment of arterial and venous thrombotic disorders.

Other names
Thrombin: Prothrombinase, Factor IIa, FIIaFactor Xa: FXa, Activated factor X, Stuart-Prower factorGeneral class: Coagulation serine proteases, Clotting factor serine proteases, Haemostatic serine proteases, Blood coagulation factors
02

Mechanism of action

Direct enzymatic inhibition (bind active site or exosites). Indirect inhibition (promote inactivation by antithrombin, e.g., heparin). Inhibition of factor synthesis (vitamin K antagonists block carboxylation of factors, rendering them inactive).

03

Biological functions

Blood coagulation (hemostasis)Conversion of fibrinogen to fibrin (via thrombin)Platelet activation (direct, thrombin)Amplification and regulation of clotting cascadeInflammatory signalingWound healing, angiogenesis, and tissue remodeling
04

Disease associations

Cardiovascular disease (thrombosis, myocardial infarction, stroke)Venous thromboembolismInflammatory disorders (including DIC, sepsis)Bleeding disorders (deficiency or dysfunction)Infection-related coagulopathiesOther: Atherosclerosis, cancer (pro-thrombotic states)
05

Safety considerations

Bleeding risk (major, clinically significant bleeding is the principal safety concern of all anticoagulants targeting these proteases)Rebound thrombosis after abrupt discontinuationDrug-drug interactions (notably with warfarin)Altered pharmacokinetics in renal/hepatic impairment (notably for some direct inhibitors)Limited reversal options for some direct inhibitors (specific antidotes now exist for some agents)Monitoring challenges (not all drugs require, or are amenable to, routine coagulation monitoring)HIT (heparin-induced thrombocytopenia; for heparin and LMWH)
06

Interacting drugs

Direct Factor Xa inhibitors: rivaroxaban, apixaban, edoxaban, betrixaban

4 more in the full profile.

07

Biomarkers

D-dimer (fibrin degradation, indirect marker)Prothrombin time (PT), International Normalized Ratio (INR, for warfarin therapy)Activated partial thromboplastin time (aPTT)Anti-FXa activity (for monitoring direct and indirect FXa inhibitors)Thrombin generation assays (research/monitoring)

Beyond the preview

Go deeper on Coagulation factor Xa and thrombin (serine proteases of coagulation) (Factor Xa (FXa), Thrombin (FIIa)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coagulation factor Xa and thrombin (serine proteases of coagulation) (Factor Xa (FXa), Thrombin (FIIa)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call